Dear Guest,

It is my honor to share our work at the NeuroLipid Research Foundation with you. Our focus is finding ways to approach challenging disorders from a cell membrane perspective. We believe that, no matter how compromised the patient, we can unravel the core of the patient’s disease/disorder and optimize his or her health status by addressing membrane fatty acid disturbances and epigenetic (toxic exposure) factors. In this way, we can determine what initiated the health problem and how we can go about resolving it.

NeuroLipid Research began with children whose treatments were abandoned as futile in conditions that included brain injury, oxygen deprivation, intractable seizures, autism, premature birth, failure to thrive, undiagnosed metabolic disorders, and more. Our work evolved to include the adult population that suffers from neurological and toxicity disorders resulting in epigenetic issues (alteration of gene expression due to toxic insult).

The current medical system often fails or dismisses complex neurological presentations. Our methodical approach moves us to delve into the medical literature to address each patient’s presentation, and to use appropriate testing to reveal unique membrane lipid disturbances, as evidenced through university-based neurochemical and epigenetic assessments. We scrutinize past laboratory tests and medical evaluations to garner a clear view of how to unravel the patient’s disturbed neuro-metabolic health problem. Our philosophy demands that we never stop trying to pinpoint what aberrations exist and the avenues we need to travel to initiate a targeted lipid protocol, so that we may optimize one’s physical and mental health.

The Neurolipid Research Foundation has directed a continuum of clinical studies for the past decade, and has been invited to present the principles of membrane medicine, based on those outcomes, to the Rare Diseases program of the National Institute of Health. We are convinced that additional formal studies will be able to support the administration of lipid therapy as a standard remedial option.

Your support is deeply appreciated.

To Your Health,

Patricia Kane, Ph.D.
Director